Skip to content
Screener

Veracyte VCYT Biopharmaceutical and other revenue — Total Revenue

Other product segments

Testing revenue
$135.09M+25.9%

Similar metrics at other companies

ImmunityBio, Inc. logo
IBRXOther revenues — Total Revenue
$39K+388%
PTH
PTHSLicense and collaboration revenues — Total Revenue
$241K—
Beazer Homes USA, Inc. logo
BZHLand sales and other revenue — Total Revenue
$25.44M+155%
TMH
TMHCAmenity and other revenue — Total Revenue
$11.93M+13.6%
ADT logo
ADTInstallation and other revenue — Total Revenue
$108.46M+13.5%
Spok Holdings logo
SPOKProduct and other revenue — Total Revenue
$917K+5.8%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.71B+97.6%
Enterprise value$3.48B+104%
P/E42.2×-29.1×
P/S6.9×+2.9×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0×0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemThree Months Ended March 31, 20262025
Revenue:
Testing revenue$135,091$107,309
Product revenue3,6793,580
Biopharmaceutical and other revenue3013,584
Total revenue139,071114,473
Cost of revenue:
Cost of testing revenue33,30628,260
Cost of product revenue1,8911,422

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's biopharmaceutical and other revenue — total revenue?
Veracyte (VCYT) reported biopharmaceutical and other revenue — total revenue of $301K in Q1 2026.
How has Veracyte's biopharmaceutical and other revenue — total revenue changed year-over-year?
Veracyte's biopharmaceutical and other revenue — total revenue decreased by 91.6% year-over-year, from $3.58M to $301K.
What is the long-term trend for Veracyte's biopharmaceutical and other revenue — total revenue?
Over 4 years (2021 to 2025), Veracyte's biopharmaceutical and other revenue — total revenue has grown at a -16.5% compound annual growth rate (CAGR), from $19.87M to $9.66M.
What does biopharmaceutical and other revenue — total revenue mean?
This metric represents the total gross revenue generated from biopharmaceutical partnerships, clinical trial services, and other non-core diagnostic product offerings. It serves as a key indicator of the company's ability to monetize its proprietary technology platform through external collaborations and research-based service agreements.

Ask your AI about Veracyte's biopharmaceutical and other revenue — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude